|
Dr. Smith joined Millennium in 2001 as Senior Vice President, Drug Safety & Disposition and Comparative Medicine with more than 20 years of experience in the U.S. pharmaceutical industry. Today, he is responsible for the preclinical development, comparative medicine and pharmaceutical sciences areas for all discovery and development programs.
Prior to joining Millennium, Dr. Smith was a Vice President at Pharmacia, where he led a global metabolism and investigative sciences department of more than 300 scientists. Previously at Searle/Monsanto, Dr. Smith led the Metabolism and Safety Evaluation department. In this role he was responsible for the preclinical development of the Cox-2 inhibitors Celebrex� and Bextra�; the antimineralocorticoid Inspra� and the glycoprotein IIb/IIIa antagonists, xemilofiban and orbofiban. Earlier in his career, Dr. Smith served as a Senior Research Toxicologist and Research Fellow in the Safety Assessment Department at Merck Research Laboratories, where he developed extensive project team experience working with leading pharmaceutical agents, including Mevacor�, Zocor�, Hyzaar�, Fosamax� and Proscar�.
Dr. Smith earned a bachelor's degree in Biology from Fairfield University, received a Ph.D. in Pharmacology and Toxicology from the University of Arizona, and completed a post-doctoral fellowship in Biochemical Toxicology at Smith Kline and French Laboratories.
| 